Evaluation: Reassessing, Measuring, and Course-Correcting
What the evaluation domain tests
Evaluation items ask what happens after the plan is implemented. Know the expected time course and objective marker for each intervention - A1c at roughly three months after a diabetes medication change, blood pressure at two to four weeks after starting an antihypertensive, PHQ-9 trending for depression, peak flow or spirometry for asthma, lipid panel after statin initiation. Distinguish treatment failure from disease progression, from a new complication, and from an adverse drug effect. Recognize adherence barriers, tolerability problems, and drug interactions that masquerade as treatment resistance. Evaluation also covers documentation, care coordination, patient satisfaction, and quality improvement.
Traps that appear in items
- Assuming improvement without reassessment, or assuming adherence without asking.
- Adding a second agent when the first was never titrated or never taken.
- Attributing a new symptom to the disease when it is a medication side effect.
- Continuing the current plan despite a red flag or abnormal monitoring value.
- Vague discharge instructions such as "return if worse" instead of specific, measurable precautions.
Rule of thumb
Every plan needs a measurable target, a timeframe, and an explicit action if the target is not met. If any of the three is missing, the plan is incomplete.
Worked example
A 62-year-old with type 2 diabetes starts metformin. At three months, A1c has fallen but remains above the individualized goal. Before intensifying therapy, verify adherence and tolerability and check renal function, since eGFR governs dosing and further options. The correct next step is to titrate or add an agent guided by comorbidity - not to switch classes blindly or to wait another year.